Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

Status Withdrawn

Clinical Trial Summary

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

Clinical Trial Description

The clinical and research need for noninvasive biomarkers in pulmonary arterial hypertension (PAH) has led the study team to develop 129Xe magnetic resonance imaging (129Xe MRI) to image pulmonary vascular pathology through quantitative 3D maps of gas transfer across the pulmonary blood-gas barrier. 129Xe MRI, in combination with 129Xe spectroscopy (MRS), has a unique signature in PAH and can simultaneously measure capillary blood volume and hemodynamic changes associated with pulmonary vascular remodeling (Wang '19a). This project aims to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is related to gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and the change in these signals over one year in patients with "stable" PAH. Our central hypothesis is that patients with "stable" PAH will display persistent abnormalities on 129Xe MRI/MRS consistent with pulmonary vascular remodeling and that some patients may have worsening of their disease while appearing to be "stable" disease. The study team will assess the ability of 129Xe MRI to longitudinally monitor disease progression in patients with "stable" PAH. First, the team will enroll "stable" PAH patients and obtain detailed clinical information to be stored in the REDCAP database. The study team will then follow this cohort of PAH subjects for one year, performing 129Xe MRI scans at baseline, 3 months, 6 months and one year in addition to their standard-of-care assessments including appointments labs, echo, and 6MWTs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06122922
Study type	Interventional
Source	Duke University
Contact
Status	Withdrawn
Phase	Phase 2
Start date	March 15, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05056532` - Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Active, not recruiting	`NCT06003244` - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)	N/A
Active, not recruiting	`NCT06072417` - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)	N/A
Recruiting	`NCT02966665` - : Vascular Function in Health and Disease	Phase 1
Recruiting	`NCT00502398` - Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?	N/A
Completed	`NCT04456998` - GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)	Phase 2
Not yet recruiting	`NCT06035861` - Endothelial Cell Activation and Total Pulmonary Resistance in PAH	N/A
Recruiting	`NCT03138863` - Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)	N/A
Recruiting	`NCT02102672` - Trimetazidine in Pulmonary Artery Hypertension	Phase 2
Recruiting	`NCT03195543` - Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
Completed	`NCT04337671` - Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension	N/A
Completed	`NCT03198910` - Retrospective Data Analysis of Data From the Zurich PH Registry
Completed	`NCT03979482` - Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Active, not recruiting	`NCT06084559` - HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)	N/A
Active, not recruiting	`NCT05996302` - HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)	N/A
Withdrawn	`NCT02684786` - A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension	Phase 1
Not yet recruiting	`NCT06258850` - REstoration of VItamin D in Pulmonary Arterial Hypertension	Phase 4
Completed	`NCT04094272` - Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Active, not recruiting	`NCT01763112` - Training With Whole Body Vibration Device in Patients With PAH	N/A
Completed	`NCT01581086` - Vascular Subphenotypes of Lung Disease in HIV & COPD	N/A